# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in valueDebt-for-equit...
Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental h...
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced an effective date for ...